Minor
Suspected
Deskripsi
Azithromycin is a weak CYP3A4 inhibitor that can modestly raise loratadine plasma levels; the clinical impact is minimal given loratadine's wide therapeutic index and low cardiac risk.
Mekanisme
Azithromycin inhibits CYP3A4 to a minor degree, reducing hepatic metabolism of loratadine; azithromycin itself carries a small QT-prolonging potential, creating a theoretical additive cardiac risk.
Signifikansi Klinis
No significant QT changes or adverse events are expected at standard doses in patients without underlying cardiac risk factors.
Penatalaksanaan
No dose adjustment required; exercise caution in patients with QT prolongation risk factors or electrolyte abnormalities.